• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白斑和口腔黏膜下纤维化中syndecan-1的免疫组织化学分析。

Immunohistochemical analysis of syndecan-1 in leukoplakia and oral submucous fibrosis.

作者信息

Kamat Sushant S, Kumar G S, Koshy Ajit V

机构信息

Department of Oral Pathology and Microbiology, Yogita Dental College and Hospital, Khed, Maharashtra, India.

出版信息

Dent Res J (Isfahan). 2013 May;10(3):321-7.

PMID:24019799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3760354/
Abstract

BACKGROUND

Syndecan-1 is abundant in normal tissues and reduced in squamous cell carcinomas. Leukoplakia and oral submucous fibrosis (OSF) are oral pre-cancerous disorders that have potential for malignant transformation. The aim of this study was to evaluate the expression of syndecan-1 in leukoplakia and OSF and to identify its role as a reliable marker for predicting malignant changes.

MATERIALS AND METHODS

Expression of syndecan-1 was examined immunohistochemically in 42 cases of oral leukoplakia with or without epithelial dysplasia, 28 cases of OSF and 10 cases of normal oral epithelia as control. Mann-Whiteny 'U' test was used for statistical analysis and the level of significance was fixed at P < 0.05.

RESULTS

Intense syndecan-1 expression was observed in nine cases with normal epithelium. Immunopositivity was lost gradually as the extent of epithelial dysplasia increased. The significant reduction in syndecan-1 expression was observed in leukoplakia as epithelial dysplasia progressed from moderate or severe. Similarly, significant reduction was observed in staining intensities in OSF with dysplasia.

CONCLUSION

The results reveal that down-regulation of syndecan-1 expression is associated with dysplastic changes in leukoplakia and OSF. Thus syndecan-1 can be considered as marker for predicting malignant changes.

摘要

背景

Syndecan-1在正常组织中含量丰富,而在鳞状细胞癌中减少。白斑和口腔黏膜下纤维化(OSF)是具有恶变潜能的口腔癌前病变。本研究的目的是评估Syndecan-1在白斑和OSF中的表达,并确定其作为预测恶变变化的可靠标志物的作用。

材料与方法

采用免疫组织化学方法检测42例伴有或不伴有上皮发育异常的口腔白斑、28例OSF以及10例正常口腔上皮作为对照中Syndecan-1的表达。采用Mann-Whiteny “U”检验进行统计学分析,显著性水平设定为P < 0.05。

结果

在9例正常上皮病例中观察到强烈的Syndecan-1表达。随着上皮发育异常程度的增加,免疫阳性逐渐消失。随着上皮发育异常从中度或重度进展,白斑中Syndecan-1表达显著降低。同样,在伴有发育异常的OSF中染色强度也显著降低。

结论

结果显示,Syndecan-1表达下调与白斑和OSF中的发育异常变化相关。因此,Syndecan-1可被视为预测恶变变化的标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/207e6d2c8bff/DRJ-10-321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/a02a6e2e78ba/DRJ-10-321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/bffd5735e621/DRJ-10-321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/3987434e6368/DRJ-10-321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/88082f29c270/DRJ-10-321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/207e6d2c8bff/DRJ-10-321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/a02a6e2e78ba/DRJ-10-321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/bffd5735e621/DRJ-10-321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/3987434e6368/DRJ-10-321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/88082f29c270/DRJ-10-321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4619/3760354/207e6d2c8bff/DRJ-10-321-g005.jpg

相似文献

1
Immunohistochemical analysis of syndecan-1 in leukoplakia and oral submucous fibrosis.白斑和口腔黏膜下纤维化中syndecan-1的免疫组织化学分析。
Dent Res J (Isfahan). 2013 May;10(3):321-7.
2
Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.伴或不伴上皮发育异常的口腔白斑中Syndecan-1下调及p53蛋白或Ki-67抗原表达的免疫组织化学研究
J Oral Pathol Med. 2003 Oct;32(9):513-21. doi: 10.1034/j.1600-0714.2003.00117.x.
3
Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis.p53和p63在口腔鳞状细胞癌、口腔白斑及口腔黏膜下纤维化中的免疫组化检测
J Investig Clin Dent. 2014 Aug;5(3):214-9. doi: 10.1111/jicd.12038. Epub 2013 Jun 18.
4
Increased expression of CK8 and CK18 in leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma: an immunohistochemistry study.CK8 和 CK18 在白斑、口腔黏膜下纤维性变和口腔鳞状细胞癌中的表达增加:免疫组织化学研究。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Feb;113(2):245-53. doi: 10.1016/j.tripleo.2011.05.034. Epub 2011 Aug 27.
5
Aberrant DKK3 expression in the oral leukoplakia and oral submucous fibrosis: a comparative immunohistochemical study.口腔白斑和口腔黏膜下纤维化中DKK3表达异常:一项比较性免疫组织化学研究。
Eur J Histochem. 2016 Jun 16;60(2):2629. doi: 10.4081/ejh.2016.2629.
6
DNA content abnormality in oral submucous fibrosis concomitant leukoplakia: A preliminary evaluation of the diagnostic and clinical implications.口腔黏膜下纤维性变伴发白斑中 DNA 含量异常:对诊断和临床意义的初步评估。
Diagn Cytopathol. 2020 Nov;48(11):1111-1114. doi: 10.1002/dc.24469. Epub 2020 May 20.
7
Role of osteopontin in oral epithelial dysplasia, oral submucous fibrosis and oral squamous cell carcinoma.骨桥蛋白在口腔上皮发育异常、口腔黏膜下纤维化及口腔鳞状细胞癌中的作用
J Oral Maxillofac Pathol. 2023 Oct-Dec;27(4):706-714. doi: 10.4103/jomfp.jomfp_492_22. Epub 2023 Dec 20.
8
Immunohistochemical detection of human telomerase reverse transcriptase in oral cancer and pre-cancer.口腔癌及癌前病变中人类端粒酶逆转录酶的免疫组织化学检测
Indian J Dent Res. 2011 Mar-Apr;22(2):362. doi: 10.4103/0970-9290.84281.
9
Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma.p21和Bcl-2在白斑、口腔黏膜下纤维化及口腔鳞状细胞癌中的免疫组织化学研究
J Exp Ther Oncol. 2016 Nov;11(4):285-292.
10
Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma.Podoplanin在口腔潜在恶性疾病和口腔鳞状细胞癌中的表达。
J Clin Exp Dent. 2017 Dec 1;9(12):e1418-e1424. doi: 10.4317/jced.54213. eCollection 2017 Dec.

引用本文的文献

1
Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research.口腔白斑中免疫组化标志物CD138和CD43的比较:一项原创研究
J Pharm Bioallied Sci. 2023 Jul;15(Suppl 1):S209-S212. doi: 10.4103/jpbs.jpbs_454_22. Epub 2023 Jul 5.

本文引用的文献

1
Plasma zinc antioxidant vitamins, glutathione levels and total antioxidant activity in oral leukoplakia.口腔白斑患者血浆锌、抗氧化维生素、谷胱甘肽水平及总抗氧化活性
Dent Res J (Isfahan). 2012 Mar;9(2):158-61. doi: 10.4103/1735-3327.95229.
2
Proliferation and apoptosis markers in oral submucous fibrosis.口腔黏膜下纤维化中的增殖与凋亡标志物
J Oral Maxillofac Pathol. 2011 May;15(2):148-53. doi: 10.4103/0973-029X.84478.
3
Reduction of syndecan-1 expression during lip carcinogenesis.在唇癌发生过程中黏附素-1 的表达减少。
J Oral Pathol Med. 2009 Aug;38(7):580-3. doi: 10.1111/j.1600-0714.2009.00761.x. Epub 2009 Mar 17.
4
Inhibition of syndecan-1 expression and function in oral cancer cells.口腔癌细胞中syndecan-1表达及功能的抑制
Oncol Rep. 2008 Dec;20(6):1353-7.
5
Oral cancer: current and future diagnostic techniques.口腔癌:当前及未来的诊断技术
Am J Dent. 2008 Aug;21(4):199-209.
6
In reference to quantitative analysis of syndecan-1 expression in dysplasia and squamous cell carcinoma of the oral cavity.关于口腔发育异常和鳞状细胞癌中syndecan-1表达的定量分析。
Laryngoscope. 2008 May;118(5):944-5; author reply 945. doi: 10.1097/MLG.0b013e318165a9f1.
7
Quantitative analysis of syndecan-1 expression in dysplasia and squamous cell carcinoma of the oral cavity.口腔发育异常及鳞状细胞癌中syndecan-1表达的定量分析。
Laryngoscope. 2007 May;117(5):868-71. doi: 10.1097/MLG.0b013e318033c810.
8
Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.Syndecan-1表达降低与口腔鳞状细胞癌深层浸润前沿的恶性组织学分级相关。
J Oral Pathol Med. 2006 May;35(5):301-6. doi: 10.1111/j.1600-0714.2006.00412.x.
9
Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas.基质硫酸乙酰肝素蛋白聚糖-1的表达是口腔癌的一个不良预后因素。
Oral Oncol. 2006 May;42(5):493-500. doi: 10.1016/j.oraloncology.2005.10.003. Epub 2005 Dec 20.
10
Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.舌鳞状细胞癌中syndecan-1表达降低与临床病理参数之间的相关性
Int J Oral Maxillofac Surg. 2006 Mar;35(3):252-7. doi: 10.1016/j.ijom.2005.06.020. Epub 2005 Nov 8.